Iraq: Levels of Tigris and Euphrates Plunge in South

People collect water for their animals from the al-Thirma river in Diwaniya, Iraq, October 11 2022. REUTERS/Alaa Al-Marjani
People collect water for their animals from the al-Thirma river in Diwaniya, Iraq, October 11 2022. REUTERS/Alaa Al-Marjani
TT

Iraq: Levels of Tigris and Euphrates Plunge in South

People collect water for their animals from the al-Thirma river in Diwaniya, Iraq, October 11 2022. REUTERS/Alaa Al-Marjani
People collect water for their animals from the al-Thirma river in Diwaniya, Iraq, October 11 2022. REUTERS/Alaa Al-Marjani

Iraq's Tigris and Euphrates rivers have witnessed a sharp decrease in their levels in the south of the country, officials said Sunday, pledging to take urgent measures to ease water shortages.

In Nasiriyah, capital of the southern province of Dhi Qar, an AFP photographer saw the river bed of the mighty Euphrates dry in patches.

The water ministry blamed the situation in some southern provinces on "the low quantity of water reaching Iraq from neighboring Türkiye".

"This has triggered a sharp drop in the country's water reserves," it said in a statement.

The Tigris and the Euphrates both have their source in Türkiye, and authorities in Iraq have long accused the Ankara government of withholding water in dams that choke the rivers, dramatically reducing flows into Iraq.

Iraqi authorities also accuse farmers of abusing water supplies and flouting restrictions to irrigate their lands.

Water scarcity hitting farming and food security are already among the "main drivers of rural-to-urban migration" in Iraq, the UN and several non-government groups said in June 2022.

According to official Iraqi statistics from last year, the level of the Tigris entering Iraq has dropped to just 35 percent of its average over the past century.

Water ministry spokesman Khaled Chamal said Sunday that Iraq was getting only 30 percent of the water it expected from the Tigris and the Euphrates.

Iraq regularly asks Türkiye to release more water, and has imposed measures to ration water for agriculture and domestic use.

Water is also often held back in dams in Iraq's north, triggering anger among residents in the south.

Chamal told AFP the latest drop in water levels in both the Tigris and Euphrates in the country's south was "temporary".

Authorities will increase levels by releasing water from Iraqi dams in the northern areas of Mosul, Dukan and Darbandikhan, he added.

"There should be positive results within the next two days," he said.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”